Tafamidis
Familial Amyloid Neuropathy
Qilu Pharmaceutical Co., Ltd.Small moleculePhase 4 / ApprovedActive
A
87/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 81/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Familial Amyloid Neuropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inotersen Akcea Therapeutics | Phase 4 | BB |
Revusiran Alnylam Pharmaceuticals | Phase 3 | BB |
Patisiran Alnylam Pharmaceuticals | Phase 3 | BB |
(1,1'-BIPHENYL)-3-CARBOXYLIC ACID, 2',4'-DIFLUORO-4-HYDROXY- Boston University | Phase 2/3 | B |
Aln-Ttrsc02 Alnylam Pharmaceuticals | Phase 3 | B |
View all 11 →
Same molecule, other indications
Tafamidis is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →